Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELECT-PsA 2: Upadacitinib vs Placebo in Biologic-IR Psoriatic Arthritis
2016-004152-30Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in psoriatic arthritis (PsA) (3 arms), sponsored by AbbVie Inc. Primary endpoint: ACR20 response. Started Jun 2017; status: completed.
02
Drugs
upadacitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2016-004152-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004152-30.